Relay Therapeutics DEF 14A: Executive Compensation Details
Ticker: RLAY · Form: DEF 14A · Filed: Apr 23, 2025 · CIK: 1812364
| Field | Detail |
|---|---|
| Company | Relay Therapeutics, Inc. (RLAY) |
| Form Type | DEF 14A |
| Filed Date | Apr 23, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, def-14a, stock-awards
TL;DR
Relay Therapeutics DEF 14A out: Executive pay details for 2024, stock awards in focus.
AI Summary
Relay Therapeutics, Inc. filed a DEF 14A on April 23, 2025, for the fiscal year ending December 31, 2024. The filing concerns executive compensation and related matters, including details on stock awards and option awards granted and vested during the covered years. Specific financial values related to these awards are detailed within the filing.
Why It Matters
This filing provides transparency into how Relay Therapeutics compensates its top executives, which can influence investor perception and employee morale.
Risk Assessment
Risk Level: medium — DEF 14A filings related to executive compensation can sometimes reveal information that impacts stock price, especially if compensation structures are unusual or tied to performance metrics.
Key Numbers
- 2024 — Fiscal Year (Reporting period for executive compensation details)
- 2023 — Fiscal Year (Comparative period for executive compensation details)
Key Players & Entities
- Relay Therapeutics, Inc. (company) — Filer of the DEF 14A
- 0000950170-25-057333 (filing_id) — Accession number for the filing
- 20250423 (date) — Filing date
- 20250606 (date) — Period of report
- 1231 (date) — Fiscal year end
FAQ
What is the primary purpose of this DEF 14A filing by Relay Therapeutics, Inc.?
The primary purpose of this DEF 14A filing is to provide information regarding the company's annual meeting of stockholders and to disclose details about executive compensation, director compensation, and corporate governance matters.
When was this DEF 14A filing submitted to the SEC?
This DEF 14A filing was submitted to the SEC on April 23, 2025.
What fiscal year does this filing primarily cover regarding compensation data?
This filing primarily covers compensation data for the fiscal year ending December 31, 2024, with comparative data for prior years.
What specific types of compensation awards are mentioned in relation to executive compensation?
The filing mentions stock awards and option awards, detailing their grant dates, vesting dates, and changes in fair value.
Where is Relay Therapeutics, Inc. headquartered?
Relay Therapeutics, Inc. is headquartered in Cambridge, MA, with a business address at 399 BINNEY STREET, 2ND FLOOR, CAMBRIDGE, MA 02139.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 23, 2025 regarding Relay Therapeutics, Inc. (RLAY).